Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 12 Sep 2022
BioLineRx announces submission of new drug application to FDA for motixafortide in stem cell mobilisation
12 September 2022 - Submission based on overwhelmingly positive top-line results from GENESIS Phase 3 trial. ...
Posted by Michael Wonder on 12 Sep 2022
ATAGI statement on use of the Moderna bivalent original/Omicron vaccine
12 September 2022 - A statement from the Australian Technical Advisory Group on Immunisation regarding COVID-19 Moderna Spikevax Bivalent Original/Omicron BA.1 ...
Posted by Michael Wonder on 12 Sep 2022
Nomination for an early re-entry resubmission - what exactly does it mean?
12 September 2022 - We compare and contrast the submissions nominated by the PBAC in March for an early re-entry ...
Posted by Michael Wonder on 12 Sep 2022
Australia's first bivalent COVID-19 vaccine to join rollout
12 September 2022 - The Australian Government has accepted a recommendation from the Australian Technical Advisory Group on Immunisation on the ...
Posted by Michael Wonder on 12 Sep 2022
PHARMAC simplifies criteria for COVID-19 anti-viral treatments
12 September 2022 - PHARMAC has confirmed today that it is simplifying the access criteria for the three anti-viral treatments it ...
Posted by Michael Wonder on 11 Sep 2022
Exits from pharmaceutical benefits on 1 October 2022
8 September 2022 - Below is a compilation of the medicines in different packaging sizes which, at the companies' own ...
Posted by Michael Wonder on 11 Sep 2022
Health movement in South Korea fights for universal access to medicines
10 September 2022 - Civil society in South Korea renewed its commitment to ensure universal access to medicines and public pharmaceutical ...
Posted by Michael Wonder on 11 Sep 2022
Inflation Reduction Act and US drug pricing
8 September 2022 - Landmark US legislation will help millions afford vital treatments. ...
Posted by Michael Wonder on 10 Sep 2022
US Food and Drug Administration approves Sotyktu (deucravacitinib), oral treatment for adults with moderate to severe plaque psoriasis
9 September 2022 - Bristol Myers Squibb’s Sotyktu, a first in class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is ...
Posted by Michael Wonder on 10 Sep 2022
Your money or your life? Cancer’s crushing cost
10 September 2022 - The first thing many cancer patients see when they arrive at the oncology ward is the EFTPOS ...
Posted by Michael Wonder on 09 Sep 2022
Health Canada approves Pfizer-BioNTech COVID-19 vaccine for kids under 5
9 September 2022 - Health Canada approves Pfizer-BioNTech COVID-19 vaccine for kids under 5. ...
Posted by Michael Wonder on 09 Sep 2022
Bausch Health responds to Norwich Pharmaceuticals tentative FDA approval for a 200 mg rifaximin
9 September 2022 - Bausch Health and its gastro-enterology business Salix Pharmaceuticals today responded to the US FDA's tentative approval ...
Posted by Michael Wonder on 09 Sep 2022
Spectrum Pharmaceuticals receives FDA approval for Rolvedon (eflapegrastim-xnst) injection
9 September 2022 - First novel long-acting G-CSF product approved in over 20 years. ...
Posted by Michael Wonder on 09 Sep 2022
FDA and EMA accept regulatory submission for Pfizer’s ritlecitinib for individuals 12 years and older with alopecia areata
9 September 2022 - Filings based on clinical data demonstrating significant scalp hair regrowth versus placebo. ...
Posted by Michael Wonder on 09 Sep 2022
Rare cancer sufferers fight to get drugs on PBS
9 September 2022 - People with rare cancers are being forced to sell their homes, raid their superannuation and fundraise ...